Eisai Co., Ltd. reported that it will absorb and merge with KAN Research Institute, Inc., the company’s wholly owned subsidiary, effective April 1, 2024.

The merger is an absorption-type merger with the company as the surviving company and KAN Research Institute as the absorbed company which dissolves as a result of the merger.

As a result of the merger, the company said that there will be no changes in the trade name, business scope, address of the head office, representative, capital, or fiscal year of the company.

The impact of the merger on the company’s consolidated financial results will be minor because the merger is a merger with the company’s wholly owned subsidiary.

Through this merger, Eisai said that it will further deepen it’s understanding of human biology, while KAN Research Institute will continue to contribute to the innovative creation as a major base of drug discovery research of the company.